NCT04978051View on ClinicalTrials.gov

Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

March 17, 2022

Conditions
COVID-19 Pneumonia
Interventions
DRUG

Firazyr

Icatibant 10 MG/ML Prefilled Syringe

OTHER

SoC

The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options

Trial Locations (1)

08907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

All Listed Sponsors
lead

Sebastian Videla

OTHER